Journal article
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1
- Abstract:
-
Background The failure of DNA vaccination in humans, in contrast to its efficacy in some species, is unexplained. Observational and interventional experimental evidence suggests that DNA immunogenicity may be prevented by binding of human serum amyloid P component (SAP). SAP is the single normal DNA binding protein in human plasma. The drug (R)-1-[6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC, miridesap), developed for treatment of syste... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
+ Medical Research Council
More from this funder
Grant:
MRC/DFIDConcordatagreements(MR-J008605/1,G1001757
MR/N023668/1
+ Department for International Development
More from this funder
Grant:
MRC/DFIDConcordatagreements(MR-J008605/1,G1001757
MR/N023668/1
Bibliographic Details
- Publisher:
- Public Library of Science Publisher's website
- Journal:
- PLoS ONE Journal website
- Volume:
- 13
- Issue:
- 5
- Article number:
- e0197299
- Publication date:
- 2018-05-17
- Acceptance date:
- 2018-04-27
- DOI:
- ISSN:
-
1932-6203
- Pmid:
-
29772028
- Source identifiers:
-
848141
Item Description
- Language:
- English
- Pubs id:
-
pubs:853654
- UUID:
-
uuid:a9191ca7-327a-4886-802d-67a0f9073e91
- Local pid:
- pubs:853654
- Deposit date:
- 2018-05-20
Terms of use
- Copyright holder:
- Borthwick et al
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 Borthwick et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record